IP Library Granted Patent US 6,911,538
Granted Patent B2
US 6,911,538 · App. 10/077,176 · Granted Jun 28, 2005

Engineered open reading frame for p53

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,911,538
App. No.
10/077,176
Granted
Jun 28, 2005
Kind
B2
Abstract

The transcription factor and tumor suppressor protein p53 is inactivated in many human cancers. Approximately forty percent of cancers carry large amounts of mutated full-length p53 protein with one of over 900 reported single amino acid changes in the p53 core domain that recognizes p53 DNA binding sites. The ability to restore function to these inactive p53 proteins would dramatically improve cancer therapy. Alternative open reading frames that are more easily engineered encode a wild-type p53. The alternative open reading frames are optimized for codon usage and expression of p53 proteins in E. coli , yeast and mammalian cells. The alternative open reading frames may additionally contain mutations that are naturally found in human cancers, substitutions that correspond to polymorphic p53 alleles, or mutations in residues that can be post-translationally modified.

Claims (2)

1. An isolated nucleic acid molecule comprising a nucleotide sequence as shown in SEQ ID NO: 1.

2. A cell comprising the nucleic acid molecule of claim 1 , wherein said cell is in in vitro culture.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 19, 2018
From: WASHINGTON UNIVERSITY IN ST. LOUIS
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 047812/0476 →
CONFIRMATORY LICENSE Recorded Dec 18, 2018
From: WASHINGTON UNIVERSITY IN ST. LOUIS
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 047949/0077 →